Rein Therapeutics, Inc. Quarterly Debt-to-equity in % from Q1 2018 to Q4 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Rein Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2018 to Q4 2023.
  • Rein Therapeutics, Inc. Debt-to-equity for the quarter ending December 31, 2023 was 9.82 %, a 39.5% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q4 2023 9.82 -6.41 -39.5% Dec 31, 2023
Q3 2023 16 +1.96 +14% Sep 30, 2023
Q2 2023 17.6 +5.87 +50.3% Jun 30, 2023
Q1 2023 19 +9.4 +98.5% Mar 31, 2023
Q4 2022 16.2 +8.25 +103% Dec 31, 2022
Q3 2022 14 +4.85 +52.9% Sep 30, 2022
Q2 2022 11.7 -3.53 -23.2% Jun 30, 2022
Q1 2022 9.55 -16.4 -63.3% Mar 31, 2022
Q4 2021 7.98 -58.7 -88% Dec 31, 2021
Q3 2021 9.17 -64.2 -87.5% Sep 30, 2021
Q2 2021 15.2 -48.6 -76.2% Jun 30, 2021
Q1 2021 26 -27.9 -51.8% Mar 31, 2021
Q4 2020 66.7 +16.1 +31.8% Dec 31, 2020
Q3 2020 73.3 +24.5 +50.2% Sep 30, 2020
Q2 2020 63.8 +15.7 +32.5% Jun 30, 2020
Q1 2020 53.9 +7.84 +17% Mar 31, 2020
Q4 2019 50.6 +19.3 +61.7% Dec 31, 2019
Q3 2019 48.8 +27.4 +128% Sep 30, 2019
Q2 2019 48.1 +34.2 +245% Jun 30, 2019
Q1 2019 46.1 -45.9 -49.9% Mar 31, 2019
Q4 2018 31.3 Dec 31, 2018
Q3 2018 21.4 Sep 30, 2018
Q2 2018 13.9 Jun 30, 2018
Q1 2018 92 Mar 31, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.